vs
Side-by-side financial comparison of Edwards Lifesciences (EW) and PAN AMERICAN SILVER CORP (PAAS). Click either name above to swap in a different company.
PAN AMERICAN SILVER CORP is the larger business by last-quarter revenue ($2.8B vs $1.6B, roughly 1.7× Edwards Lifesciences).
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
EW vs PAAS — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2022
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $2.8B |
| Net Profit | $380.7M | — |
| Gross Margin | 78.0% | 27.0% |
| Operating Margin | 1.8% | — |
| Net Margin | 23.1% | — |
| Revenue YoY | 16.7% | — |
| Net Profit YoY | 6.8% | — |
| EPS (diluted) | $0.66 | $-1.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — |
| Q1 26 | $380.7M | — | ||
| Q4 25 | $91.2M | — | ||
| Q3 25 | $291.1M | — | ||
| Q2 25 | $333.2M | — | ||
| Q1 25 | $358.0M | — | ||
| Q4 24 | $385.6M | — | ||
| Q3 24 | $3.1B | — | ||
| Q2 24 | $366.3M | — |
| Q1 26 | 78.0% | — | ||
| Q4 25 | 78.1% | — | ||
| Q3 25 | 77.8% | — | ||
| Q2 25 | 77.5% | — | ||
| Q1 25 | 78.7% | — | ||
| Q4 24 | 78.9% | — | ||
| Q3 24 | 80.6% | — | ||
| Q2 24 | 79.9% | — |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 9.6% | — | ||
| Q3 25 | 19.8% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 27.9% | — | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 25.9% | — | ||
| Q2 24 | 26.8% | — |
| Q1 26 | 23.1% | — | ||
| Q4 25 | 5.8% | — | ||
| Q3 25 | 18.7% | — | ||
| Q2 25 | 21.7% | — | ||
| Q1 25 | 25.3% | — | ||
| Q4 24 | 27.8% | — | ||
| Q3 24 | 226.7% | — | ||
| Q2 24 | 26.7% | — |
| Q1 26 | $0.66 | — | ||
| Q4 25 | $0.16 | — | ||
| Q3 25 | $0.50 | — | ||
| Q2 25 | $0.56 | — | ||
| Q1 25 | $0.61 | — | ||
| Q4 24 | $0.65 | — | ||
| Q3 24 | $5.13 | — | ||
| Q2 24 | $0.61 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
